The HIMS app arranged on a smartphone in New York on February 12, 2025.
Gabby Jones | Bloomberg | Getty pictures
Hims & Hers Health The shares closed 5%on Tuesday after the company announced that patients can access Eli Lilly'S weight loss medication zepbound and diabetes medication Mounjaro and the generic injection liraglutid via its platform.
Zepbound, Mounjaro and Liraglutid are part of the class of weight loss medication, which are referred to as GLP-1 and are increasingly popular in recent years. Hims & Her started a weight loss program at the end of 2023, but its GLP 1 offers have developed because the company struggled with volatile care and regulatory environment.
Lilly's weekly injections Zepbound and Mounjaro, according to the HIMS & HERS website, cost patients 1,899 US dollars per month. The generic liraglutide costs $ 299 a month, but requires a daily injection and can be less effective than other GLP 1 medication.
“If we look ahead, we plan to further expand our weight loss offer in order to have an even more holistic, personalized experience,” wrote Dr. Craig Primack, Senior Vice President for weight loss at HIMS & HOR, in a blog post.
A Lilly spokesman said in a statement that the company had “no belonging” to HIMS & Heck and found that Zepbound for people who are insured for the product or for those who buy directly from the company are available at lower costs.
Hims & Hers, reinforced Semaglutid, began in May, the active ingredient in Novo Nordisks GLP-1 weight loss medication Ozempic and Wegovy. The offer was immensely popular and in 2024 contributed to generating sales of more than 225 million US dollars for the company.
However, composite medication can traditionally only be produced if the treatments of the branded medication are lacking in deficiency. The US Food and Drug Administration announced in February that the lack of semaglutidinjection products had been solved.
This meant that HIMS & HINS had to stop offering the composed medication, although some consumers may continue to access personalized cans if they are clinically applicable.
During the quarterly call of the company with investors in February, HIMS & HERS said that his weight loss offer would primarily consist of her oral medication and liraglutide. The company expects its weight loss offer to achieve at least 725 million dollars to annual sales, without contributions from Compounded Semaglutid.
However, the company is still committed to increased medication. A pop -up on the HIMS & HERS website viewed by CNBC encourages users to “use their voice” and to demand the congress and the FDA to preserve access to compound treatments.
With the rally on Tuesday, Hims and Heus rose by 27% in 2025 after increasing by 172% last year.
REGARD: HIMS & HERS is divided into concerns about the weight loss transaction
